Onkológia 6/2018
News in systemic treatment of ovarian cancer
Epithelial ovarian cancer (EOC) includes ovarian, ovarian, and primary peritoneal carcinoma. Standard systemic treatment consists of platinum-based chemotherapy with the possibility of adding anti-angiogenic antibody bevacizumab (anti-VEGF antibody). Standard care for patients with platinum-refractory disease includes monotherapy with non-platinum cytostatics in combination with or without bevacizumab. Other targeted molecules in EOC treatment include pazopanib - oral multi-target tyrosine kinase inhibitor (TKI) receptor for vascular endothelial growth factor (VEGFR) and cediranib, oral TKI VEGFR and c-kit. Poly-ADP-ribose polymerase (PARP) inhibitors represent another new therapeutic group in the treatment of ovarian carcinoma used in particular for the treatment of tumors with inactivating mutations in BRCA1/2 genes. Due to the unsatisfactory results of treatment of platina refractory or relapsing EOC, new therapeutic options are currently being sought. Treatment with immune checkpoint inhibitors is the subject of several ongoing phase II and III studies.
Keywords: epithelial ovarian cancer, target therapy, BRCA mutation, PARP inhibitors, imunotherapy












